Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease

June 17, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search